Dashboard
Manage Tickers

APLSApellis Pharmaceuticals, Inc.


$ 35.64 $ 0.10 (0.28 %)    

Wednesday, 18-Sep-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 472.49 $ -2.05 (-0.43 %)
DIA $ 416.26 $ -1.07 (-0.26 %)
SPY $ 562.20 $ -1.67 (-0.3 %)
TLT $ 99.62 $ -1.25 (-1.24 %)
GLD $ 235.53 $ -1.83 (-0.77 %)
$ 35.63
$ 35.36
$ 35.62 x 100
-- x --
$ 35.36 - $ 37.05
$ 33.49 - $ 73.80
826,630
na
4.34B
$ 0.89
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

analyst-scoreboard-15-ratings-for-apellis-pharmaceuticals
Analyst Scoreboard: 15 Ratings For Apellis...
09/13/2024 21:01:00

jp-morgan-maintains-overweight-on-apellis-pharmaceuticals-lowers-price-target-to-57
JP Morgan Maintains Overweight on Apellis ...
09/13/2024 19:24:30

JP Morgan analyst Anupam Rama maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Overweight and lowers the price target ...

jp-morgan-maintains-overweight-on-apellis-pharmaceuticals-lowers-price-target-to-64
JP Morgan Maintains Overweight on Apellis ...
08/13/2024 12:31:23

JP Morgan analyst Anupam Rama maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Overweight and lowers the price target ...

ubs-maintains-buy-on-apellis-pharmaceuticals-lowers-price-target-to-83
UBS Maintains Buy on Apellis Pharmaceutica...
08/09/2024 14:48:37

UBS analyst Eliana Merle maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $85 to ...

wedbush-maintains-neutral-on-apellis-pharmaceuticals-raises-price-target-to-41
Wedbush Maintains Neutral on Apellis Pharm...
08/09/2024 13:58:51

Wedbush analyst Laura Chico maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and raises the price target from ...

goldman-sachs-maintains-buy-on-apellis-pharmaceuticals-raises-price-target-to-74
Goldman Sachs Maintains Buy on Apellis Pha...
08/09/2024 11:57:44

Goldman Sachs analyst Salveen Richter maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and raises the price target...

baird-maintains-outperform-on-apellis-pharmaceuticals-raises-price-target-to-96
Baird Maintains Outperform on Apellis Phar...
08/09/2024 11:15:20

Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and raises the price target fro...

needham-reiterates-buy-on-apellis-pharmaceuticals-maintains-85-price-target
Needham Reiterates Buy on Apellis Pharmace...
08/09/2024 10:31:19

Needham analyst Joseph Stringer reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $85 price target.

apellis-pharmaceuticals-pegcetacoplan-meets-primary-goal-in-late-stage-study-in-patients-with-rare-kidney-diseases
Apellis Pharmaceuticals' Pegcetacoplan Mee...
08/08/2024 16:53:31

Swedish Orphan Biovitrum and Apellis Pharmaceuticals released topline results from the Phase 3 VALIANT study of pegcetacoplan f...

trading-halt-halt-status-updated-at-72500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 7:25:...
08/08/2024 11:25:03

apellis-and-sobi-announce-phase-3-valiant-study-results-for-pegcetacoplan-in-rare-kidney-diseases-achieves-68-reduction-in-proteinuria-consistent-across-all-subgroups-data-submission-planned-for-us-and-eu
Apellis And Sobi Announce Phase 3 VALIANT ...
08/08/2024 11:20:25

Apellis To Host Conference Call At 8:00 AM ET

trading-halt-halted-at-65500-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 6:55:00 a.m. ET - ...
08/08/2024 10:55:03

hc-wainwright--co-maintains-buy-on-apellis-pharmaceuticals-lowers-price-target-to-83
HC Wainwright & Co. Maintains Buy on Apell...
08/02/2024 21:21:55

HC Wainwright & Co. analyst Douglas Tsao maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price...

goldman-sachs-maintains-buy-on-apellis-pharmaceuticals-lowers-price-target-to-66
Goldman Sachs Maintains Buy on Apellis Pha...
08/02/2024 16:24:24

Goldman Sachs analyst Salveen Richter maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target...

critical-insights-from-apellis-pharmaceuticals-analyst-ratings-what-you-need-to-know
Critical Insights From Apellis Pharmaceuti...
08/02/2024 12:00:16

needham-reiterates-buy-on-apellis-pharmaceuticals-maintains-85-price-target
Needham Reiterates Buy on Apellis Pharmace...
08/02/2024 10:53:13

Needham analyst Joseph Stringer reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $85 price target.

correction-apellis-pharmaceuticals-q2-2024-gaap-eps-030-beats-032-estimate-sales-19970m-beat-19151m-estimate
CORRECTION: Apellis Pharmaceuticals Q2 202...
08/01/2024 12:06:04

jefferies-maintains-buy-on-apellis-pharmaceuticals-maintains-80-price-target
Jefferies Maintains Buy on Apellis Pharmac...
07/31/2024 18:04:23

Jefferies analyst Akash Tewari maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $80 price target.

watching-apellis-pharmaceuticals-traders-circulate-comments-from-jefferies-suggesting-the-fda-has-put-out-a-faers-update-which-included-a-new-additional-death-on-syfovre-says-does-not-change-our-view-on-syfovres-safety
Watching Apellis Pharmaceuticals; Traders ...
07/31/2024 14:55:34

https://fis.fda.gov/sense/app/95239e26-e0be-42d9-a960-9a5f7f1c25ee/sheet/45beeb74-30ab-46be-8267-5756582633b4/state/analysis

baird-maintains-outperform-on-apellis-pharmaceuticals-lowers-price-target-to-86
Baird Maintains Outperform on Apellis Phar...
07/26/2024 11:15:29

Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and lowers the price target fro...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION